Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 16/20 | 0.88 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.88 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.88 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.88 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.88 |
| ▸ | DRD1 | P21728 | 1/20 | 0.88 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.88 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.88 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.88 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.88 |
| ▸ | DRD3 | P35462 | 1/20 | 0.88 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.88 |
| ▸ | MTR | Q99707 | 1/20 | 0.88 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lomitapide SCHEMBL304604 | 0.94 | MTTP (1.00) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| Lomitapide SCHEMBL29355521 | 0.94 | MTTP (1.00) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL19500372 | 0.93 | MTTP (0.76) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| Lomitapide SCHEMBL29367678 | 0.90 | MTTP (1.00) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| Lomitapide SCHEMBL2731380 | 0.90 | MTTP (1.00) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL16519940 | 0.88 | MTTP (0.88) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL15579415 | 0.87 | MTTP (0.84) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL6600443 | 0.87 | MTTP (0.86) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL6188141 | 0.86 | MTTP (0.85) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL6603726 | 0.86 | MTTP (0.85) | MTTPCHRM2ADRA2AADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305858-A1 | AMORPHOUS FORM OF LOMITAPIDE MESYLATE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305858-A1 | AMORPHOUS FORM OF LOMITAPIDE MESYLATE | LIPA, AUP1, LPXN | MTTP 4/4885CHRM2 3681/4885ADRA2A 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.